Immatics (IMTX) to Release Quarterly Earnings on Tuesday

Immatics (NASDAQ:IMTX) is anticipated to post its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect Immatics to post earnings of ($0.42) per share and revenue of $9.7930 million for the quarter. Individuals may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Wednesday, May 13, 2026 at 12:30 PM ET.

Immatics (NASDAQ:IMTX) last issued its quarterly earnings data on Thursday, March 5th. The company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.14. Immatics had a negative net margin of 411.90% and a negative return on equity of 41.81%. The firm had revenue of $23.18 million for the quarter, compared to analyst estimates of $12.18 million. On average, analysts expect Immatics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Immatics Stock Down 1.9%

NASDAQ:IMTX traded down $0.22 during mid-day trading on Tuesday, reaching $10.93. 219,242 shares of the company were exchanged, compared to its average volume of 426,446. Immatics has a 12 month low of $3.94 and a 12 month high of $12.41. The company has a fifty day moving average of $10.29 and a 200 day moving average of $10.11. The stock has a market cap of $1.46 billion, a PE ratio of -5.94 and a beta of 1.31.

Analyst Ratings Changes

A number of equities research analysts have commented on the stock. TD Cowen initiated coverage on shares of Immatics in a report on Tuesday, April 28th. They set a “buy” rating on the stock. Wall Street Zen downgraded shares of Immatics from a “hold” rating to a “sell” rating in a research report on Saturday. Mizuho set a $25.00 target price on shares of Immatics in a research report on Thursday, February 19th. Jefferies Financial Group initiated coverage on shares of Immatics in a research report on Monday, March 16th. They set a “buy” rating and a $18.00 target price on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Immatics in a research report on Thursday, January 22nd. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Immatics has an average rating of “Moderate Buy” and a consensus target price of $19.00.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Vanguard Personalized Indexing Management LLC raised its position in shares of Immatics by 3.7% in the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 49,374 shares of the company’s stock valued at $518,000 after acquiring an additional 1,739 shares during the period. Bank of America Corp DE raised its position in shares of Immatics by 166.0% in the 4th quarter. Bank of America Corp DE now owns 3,575 shares of the company’s stock valued at $25,000 after acquiring an additional 2,231 shares during the period. Barclays PLC raised its position in shares of Immatics by 11.4% in the 4th quarter. Barclays PLC now owns 28,185 shares of the company’s stock valued at $296,000 after acquiring an additional 2,874 shares during the period. Virtus Investment Advisers LLC raised its position in shares of Immatics by 43.0% in the 4th quarter. Virtus Investment Advisers LLC now owns 26,497 shares of the company’s stock valued at $278,000 after acquiring an additional 7,965 shares during the period. Finally, Quarry LP acquired a new stake in shares of Immatics in the 4th quarter valued at approximately $84,000. 64.41% of the stock is currently owned by institutional investors and hedge funds.

About Immatics

Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.

At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.